Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.

Authors: S. Vincent Rajkumar Voorhees, Peter Michael Goldschmidt, Hartmut Baker, Ross I. Bandekar, Rajesh Kuppens, Steven and Neff, Tobias Qi, Ming Dimopoulos, Meletios A.
Publication date: 1 January 2018
Publisher

Abstract

Abstract is not available.

Similar works

Full text

thumbnail-image

Available Versions

Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

redirect

oai

oai:lib.uoa.gr:uoadl:3179876

Last time updated on 10/02/2023